Royalty Pharma plc (RPRX) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	2.5B	2.4B	2.3B	2.4B	2.2B
Cost of Revenue	269.4M	—	—	—	—
Gross Profit	2.3B	2.4B	2.3B	2.4B	2.2B
Operating Expenses
R&D Expense	239.4M	452.0M	2.0M	52.0M	177.1M
SG&A Expense	603.9M	573.5M	236.7M	249.7M	227.3M
General & Admin Expense	603.9M	573.5M	236.7M	249.7M	227.3M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(157.3M)	(206.8M)	732.5M	560.7M	1.5B
Total Operating Expenses	685.5M	818.7M	971.1M	862.4M	1.9B
Cost and Expenses	954.9M	818.7M	971.1M	862.4M	1.9B
Operating Income (EBIT)	1.6B	1.6B	1.3B	1.5B	307.1M
Non-Operating
Interest Income	25.3M	33.6M	47.3M	72.3M	78.3M
Interest Expense	361.1M	307.7M	225.5M	187.2M	188.0M
Net Interest Income	(335.7M)	(274.1M)	(178.2M)	(114.9M)	(109.6M)
Other Non-Op Income/Expense	(231.3M)	(235.3M)	38.4M	207.9M	(77.0M)
Non-Operating Income (excl Interest)	(129.8M)	(72.3M)	(263.9M)	(395.1M)	(111.0M)
EBT (Pre-Tax Income)	1.3B	1.3B	1.3B	1.7B	230.1M
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	815.3M	770.9M	859.0M	1.1B	42.8M
Earnings from Cont. Ops	1.3B	1.3B	1.3B	1.7B	230.1M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	967.8M	1.0B	1.1B	1.5B	42.8M
Per Share
Basic EPS	$2.41	$2.33	$1.92	$3.41	$0.10
Diluted EPS	$1.74	$1.80	$1.91	$2.53	$0.10
Revenue Per Share	$5.70	$5.51	$5.08	$5.26	$5.11
Shares
Basic Shares Outstanding	445.1M	431.9M	446.0M	447.6M	438.0M
Diluted Shares Outstanding	556.9M	559.6M	594.0M	602.9M	564.9M
Profitability Metrics
EBITDA	1.7B	1.6B	1.6B	1.9B	423.7M
D&A	4.9M	3.9M	—	—	5.7M
EBIT	1.7B	1.6B	1.6B	1.9B	418.0M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026